{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:42:48Z","timestamp":1779907368611,"version":"3.53.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020940","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees","doi-asserted-by":"publisher","award":["OoR2022\/100004"],"award-info":[{"award-number":["OoR2022\/100004"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006221","name":"United States - Israel Binational Science Foundation","doi-asserted-by":"publisher","award":["2019303"],"award-info":[{"award-number":["2019303"]}],"id":[{"id":"10.13039\/100006221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1615\/19"],"award-info":[{"award-number":["1615\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["20-0238"],"award-info":[{"award-number":["20-0238"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","award":["846497"],"award-info":[{"award-number":["846497"]}],"id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001742","name":"United States-Israel Binational Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijbiomac.2025.145693","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:21:08Z","timestamp":1751372468000},"page":"145693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Structural analysis of nanobody interactions with their prostate-specific membrane antigen binding epitopes"],"prefix":"10.1016","volume":"320","author":[{"given":"Gal","family":"Alon-Zchut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truc T.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Weizmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raz","family":"Zarivach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niv","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.145693_bb0005","series-title":"Global cancer observatory: Cancer today. Https:\/\/Gco.Iarc.Who.Int\/Today 2024(Apr 21)","author":"Ferlay","year":"2024"},{"issue":"23","key":"10.1016\/j.ijbiomac.2025.145693_bb0010","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.7150\/thno.36739","article-title":"PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery","volume":"9","author":"Derks","year":"2019","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145693_bb0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/acs.bioconjchem.9b00758","article-title":"Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers?","volume":"31","author":"Hensbergen","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145693_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145693_bb0025","first-page":"349","article-title":"[68Ga]ga-PSMA-11 in prostate cancer: a comprehensive review","volume":"10","author":"Bois","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.15415\/jnp.2018.61020","article-title":"In silicoAnalysis of the structural properties of PSMA and its energetic relationship with zn as cofactor","volume":"6","author":"Fuentes","year":"2018","journal-title":"Journal of Nuclear Physics, Material Science, Radiation and Application"},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.145693_bb0035","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.145693_bb0040","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy","volume":"100","author":"Sch\u00fclke","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145693_bb0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/pros.20361","article-title":"Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro","volume":"66","author":"Yao","year":"2006","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145693_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.21065","article-title":"Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid","volume":"70","author":"Yao","year":"2010","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145693_bb0055","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U","article-title":"Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells","volume":"45","author":"Lapidus","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0060","series-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular Endothelium1","author":"Liu","year":"1997"},{"issue":"21","key":"10.1016\/j.ijbiomac.2025.145693_bb0065","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145693_bb0070","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2003","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145693_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hyb.2007.0522","article-title":"Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use","volume":"26","author":"Moffett","year":"2007","journal-title":"Hybridoma"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.145693_bb0080","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1158\/1078-0432.CCR-06-2935","article-title":"Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors","volume":"13","author":"Morris","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Pandit-Taskar","year":"2015","journal-title":"EJNMMI Res."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.145693_bb0090","doi-asserted-by":"crossref","first-page":"7195s","DOI":"10.1158\/1078-0432.CCR-1004-0023","article-title":"Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity","volume":"11","author":"Vallabhajosula","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.145693_bb0095","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.145693_bb0100","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.urolonc.2020.05.028","article-title":"Phase I trial of docetaxel plus lutetium-177-labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"38","author":"Batra","year":"2020","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145693_bb0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.2020-0028","article-title":"Pilot study of hyperfractionated dosing of lutetium-177\u2013labeled antiprostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"25","author":"Niaz","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145693_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.117.191874","article-title":"Why targeting PSMA is a game changer in the management of prostate cancer","volume":"59","author":"Donin","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145693_bb0115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.145693_bb0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.copbio.2011.06.009","article-title":"Immuno-imaging using nanobodies - ScienceDirect","volume":"22","author":"Vaneycken","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2019","journal-title":"BioDrugs"},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.145693_bb0130","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1021\/acs.jmedchem.0c00418","article-title":"Nanobodies targeting prostate-specific membrane antigen for the imaging and therapy of prostate cancer","volume":"63","author":"Rosenfeld","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108913","article-title":"PSMA-reactive NB7 single domain antibody fragment: a potential scaffold for developing prostate cancer theranostics","volume":"134-135","author":"Huynh","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145693_bb0140","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1074\/jbc.M111.242818","article-title":"Dual beneficial effect of interloop disulfide bond for single domain antibody fragments *","volume":"287","author":"Govaert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0145","series-title":"J2 Nanobodies to study G Protein\u2013Coupled receptor structure and function. Annual Review of Pharmacology and Toxicology, 57","first-page":"19","author":"Manglik","year":"2017"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26338-z","article-title":"The structural basis of nanobody unfolding reversibility and thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145693_bb0155","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu] lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145693_bb0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145693_bb0165","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"7873","key":"10.1016\/j.ijbiomac.2025.145693_bb0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.145693_bb0175","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1111\/j.1742-4658.2009.07152.x","article-title":"Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III","volume":"276","author":"Hlouchova","year":"2009","journal-title":"FEBS J."},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.145693_bb0180","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.bmc.2014.05.061","article-title":"Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery","volume":"22","author":"Tykvart","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.145693_bb0185","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0190","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1038\/s41467-021-25746-6","article-title":"A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.145693_bb0195","doi-asserted-by":"crossref","first-page":"11130","DOI":"10.1093\/nar\/gkaa494","article-title":"Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer","volume":"48","author":"Ptacek","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tibs.2014.10.005","article-title":"How cryo-EM is revolutionizing structural biology","volume":"40","author":"Bai","year":"2015","journal-title":"Trends Biochem. Sci."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.145693_bb0205","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain fv analogue produced in escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.145693_bb0210","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/jps.21635","article-title":"Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability","volume":"98","author":"Gursahani","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145693_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110085","article-title":"How structure defines affinity in protein-protein interactions","volume":"9","author":"Erijman","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145693_bb0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00276625","article-title":"Allostery without conformational change - a plausible model","volume":"11","author":"Cooper","year":"1984","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0225","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","article-title":"Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy","volume":"48","author":"Ruigrok","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145693_bb0230","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MNM.0000000000001658","article-title":"Kidney absorbed radiation doses for [177Lu] lu-PSMA-617 and [177Lu] lu-PSMA-I&T determined by 3D clinical dosimetry","volume":"44","author":"Uijen","year":"2023","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0235","first-page":"1032432","article-title":"Clare DK & Orlova EV (2017) structural study of heterogeneous biological samples by cryoelectron microscopy and image processing","volume":"1","author":"White","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145693_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2021.12.005","article-title":"Quantitative mining of compositional heterogeneity in cryo-EM datasets of ribosome assembly intermediates","volume":"30","author":"Rabuck-Gibbons","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102815","article-title":"Confronting heterogeneity in cryogenic electron microscopy data: innovative strategies and future perspectives with data-driven methods","volume":"86","author":"Kimanius","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.145693_bb0255","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.145693_bb0260","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145693_bb0265","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ijbiomac.2025.145693_bb0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.145693_bb0275","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallographica Section D: Structural Biology"},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.145693_bb0280","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.145693_bb0285","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.145693_bb0290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15171\/bi.2016.17","article-title":"Tips on ligand immobilization and kinetic study using surface plasmon resonance","volume":"6","author":"Ezzati Nazhad Dolatabadi","year":"2016","journal-title":"Bioimpacts"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.145693_bb0295","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/pro.2230","article-title":"Protein\u2013protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area","volume":"22","author":"Chen","year":"2013","journal-title":"Protein Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025062488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025062488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:24:46Z","timestamp":1766827486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025062488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"alternative-id":["S0141813025062488"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145693","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural analysis of nanobody interactions with their prostate-specific membrane antigen binding epitopes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"145693"}}